Trump Picks Dr. Heidi Overton, Top White House Aide, To Lead The FDA/ TezzBuzz/ WASHINGTON/ J. Mansour/ President Donald Trump selected White House domestic policy aide Dr. Heidi Overton to lead the Food and Drug Administration. Overton has promoted Trump’s drug-pricing and vaccine initiatives and previously criticized abortion pills, placing her at the center of several contentious health debates. If confirmed, she will inherit disputes involving vaccines, vaping, antidepressants, drug approvals, peptides, ultraprocessed foods and major foodborne illness outbreaks.
Quick Look
- Trump nominated Dr. Heidi Overton to lead the FDA.
- Overton is a physician and senior White House aide.
- She serves as deputy director of the Domestic Policy Council.
- She previously worked at the America First Policy Institute.
- Trump called her a respected “rockstar.”
- Overton supported Trump’s drug-pricing initiatives.
- She appeared with Trump for his controversial MMR vaccine order.
- Medical groups oppose separating the combined MMR vaccine.
- Scientific evidence shows vaccines do not cause autism.
- Overton has criticized abortion pills.
- She could reconsider rules expanding access to those medications.
- The Senate must confirm her nomination.
- Sen. Bill Cassidy may question her on vaccine policy.
- She would replace Dr. Marty Makary, who resigned in May.
- The FDA faces disputes involving vaping and nicotine products.
- Drug companies want faster and more predictable approvals.
- MAHA supporters want easier access to certain peptides.
- FDA scientists warn those peptides lack adequate safety evidence.
- The agency is working on a definition of ultraprocessed food.
- The FDA is investigating major cyclospora and salmonella outbreaks.
Deep Look
Trump chooses Overton to lead FDA
President Donald Trump announced Wednesday that he had selected Dr. Heidi Overton, a senior White House aide, to become commissioner of the Food and Drug Administration.
Overton is a medical doctor and deputy director of the White House Domestic Policy Council.
She has worked on several of Trump’s second-term health initiatives and emerged as a trusted administration official.
The position requires Senate confirmation.
Trump calls Overton a ‘rockstar’
Trump referred to his nominee as “Dr. Heidi” in a Truth Social announcement.
He described Overton as a smart and respected “rockstar.”
Trump said she would advance his priorities involving faster cures, medical innovation, lower prescription drug prices and Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again movement.
If confirmed, Overton would take charge of an agency regulating medicines, vaccines, medical devices, tobacco and much of the nation’s food supply.
Competing interests await nominee
The next FDA commissioner will need to balance several conflicting political demands.
Trump has personal priorities involving vaccines, drug prices and the speed of medical approvals.
Traditional Republicans frequently favor reducing regulation and giving businesses greater flexibility.
Kennedy and the MAHA movement often take a more anti-corporate position, particularly toward pharmaceutical companies and the food industry.
Those competing pressures complicated the tenure of former Commissioner Dr. Marty Makary.
Overton has medical and policy background
Overton attended medical school at the University of New Mexico, according to her LinkedIn profile.
She also earned a doctorate in clinical investigation from Johns Hopkins University in Maryland.
Before joining Trump’s second administration, she served as chief policy officer at the conservative America First Policy Institute.
Her combination of medical training, policy experience and close ties to the White House distinguishes her from nominees primarily drawn from academia or the pharmaceutical industry.
Overton promotes drug-pricing agreements
Overton has appeared alongside Trump during announcements of major health initiatives.
Those included the administration’s “most favored nation” agreements with pharmaceutical companies.
The deals aim to reduce U.S. drug prices to levels paid in other developed countries.
Trump has made lower medication costs a central goal, though drug companies have warned that aggressive pricing restrictions could reduce investment in research.
Nominee backed controversial vaccine order
Overton also appeared with Trump when he announced an order seeking to divide the combined measles, mumps and rubella vaccine into three separate shots.
Medical organizations oppose that change.
They say the combined MMR vaccine has an established safety record and that splitting it would create significant logistical and financial challenges.
The proposal could also make it harder for children to receive all recommended immunizations on schedule.
Trump repeats false autism suggestion
During the Oval Office event, Overton stood beside Trump as he falsely suggested that the number or timing of vaccines could be contributing to rising autism diagnoses.
Scientific consensus and decades of research have found no connection between vaccines and autism spectrum disorder.
The episode could become a focus of Overton’s Senate confirmation hearing.
Lawmakers may ask whether she supports evidence-based vaccine policy when it conflicts with Trump’s public claims.
Overton has criticized abortion pills
Overton has previously criticized medication abortion.
If confirmed, she would be positioned to reconsider FDA policies that made abortion pills easier to obtain.
Abortion opponents have complained that the Trump administration has not done enough to restrict medications prescribed online and delivered across state lines.
They argue that broad access to abortion pills undermines state bans.
Supporters of medication abortion say the drugs are safe and essential to reproductive healthcare.
Cassidy could scrutinize vaccine positions
Overton must secure approval from the narrowly Republican-controlled Senate.
She will first face questioning from the Senate health committee.
Its chairman, Louisiana Republican Sen. Bill Cassidy, is a physician.
Cassidy has criticized several Trump actions that cast doubt on vaccines, including the recent MMR order.
His position could make vaccine policy one of the most important issues during Overton’s confirmation process.
Makary left unfinished projects
Overton would replace Makary, who resigned in May.
He departed with several major initiatives incomplete.
The FDA was still working on policies involving ultraprocessed foodsantidepressants and COVID-19 vaccines.
Makary also faced criticism from pharmaceutical executives, abortion opponents and other groups over the agency’s direction.
Vaping dispute contributed to frustration
Tensions surrounding Makary intensified over flavored electronic cigarettes.
Manufacturers such as R.J. Reynolds want to market some products as alternatives for adult smokers.
Public health advocates blame sweet-flavored vapes for encouraging nicotine use among teenagers.
FDA scientists were hesitant to approve those products as smoking-cessation alternatives without stronger evidence of public health benefits.
FDA bypassed staff experts
Days before Makary resigned, the FDA opened the possibility of allowing more unauthorized e-cigarettes and nicotine pouches onto the American market.
The policy change largely bypassed the agency’s scientific staff.
That approach raised questions about whether political officials were overriding career experts.
Overton will need to determine whether to continue, revise or reverse the policy.
Biotech industry wants approval changes
Pharmaceutical and biotechnology companies are also pressing for changes at the FDA.
The agency has rejected or reversed decisions on several treatments for rare diseases.
Biotech companies, investors and patient organizations argue that the FDA has become unpredictable and overly cautious.
Conservative lawmakers have amplified those complaints.
Makary responded by announcing programs intended to accelerate or simplify drug approvals, but some created additional challenges for the agency.
Senior FDA officials departed
Several senior officials left the FDA during Makary’s tenure.
Dr. Vinay Prasad, who oversaw vaccines and biotechnology products, resigned in April following intense criticism from drug companies, investors and patients.
Dr. Tracy Beth Hoeg was involved in reviews of antidepressants, COVID-19 vaccines and other widely used treatments.
She was later replaced as acting director of the FDA’s drug center.
The departures added to concerns about leadership stability and scientific continuity.
MAHA seeks easier peptide access
Kennedy’s Make America Healthy Again movement has high expectations for the next commissioner.
A major pending decision involves the regulation of peptides promoted by wellness influencers and celebrities.
Federal advisers selected by Kennedy recently recommended easing access to several of the compounds.
FDA scientists have warned that the products have not been proven safe or effective.
Overton will need to decide whether to follow the advisers’ recommendation or the agency scientists’ cautions.
Food ingredient rules remain unfinished
The FDA recently proposed requiring food companies to notify regulators before introducing new ingredients or additives into processed and packaged foods.
The agency is also working with the White House to establish the first federal definition of ultraprocessed food.
Kennedy argues that such foods contribute to elevated rates of obesity, diabetes and other chronic illnesses.
A formal definition could become the foundation for new labeling, regulatory or dietary policies.
Vaccine research faces new barriers
Under Kennedy, the FDA has added hurdles to vaccine testing and blocked publication of research examining the effectiveness of COVID-19 shots.
Kennedy also stood with Trump as the president signed the executive order aimed at reshaping childhood vaccination practices.
Public health experts warn that the plan presents unprecedented logistical and financial challenges.
Overton would inherit responsibility for implementing the order while maintaining the FDA’s scientific standards.
Antidepressant review continues
The agency is conducting an ongoing review of widely used antidepressants.
Officials are examining whether use during pregnancy could increase the risk of autism or other conditions in children.
Kennedy has long criticized antidepressants and previously led the anti-vaccine movement before joining the administration.
The review could affect medication warnings and prescribing practices, though any regulatory decision would require strong scientific evidence.
Foodborne illness investigations remain active
The FDA is also investigating two large summertime foodborne disease outbreaks.
A cyclospora outbreak linked to contaminated iceberg lettuce has sickened thousands of people.
Jalapeño peppers have been connected to a separate multistate salmonella outbreak.
Managing those investigations will be among the agency’s immediate public health responsibilities while Overton’s nomination moves through the Senate.
More on US News